NS Partners Ltd Sells 6,261 Shares of IDEXX Laboratories, Inc. $IDXX

NS Partners Ltd lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.8% during the second quarter, Holdings Channel reports. The firm owned 28,950 shares of the company’s stock after selling 6,261 shares during the quarter. NS Partners Ltd’s holdings in IDEXX Laboratories were worth $15,240,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth approximately $25,000. SHP Wealth Management bought a new stake in IDEXX Laboratories in the fourth quarter valued at $26,000. Elevation Wealth Partners LLC boosted its holdings in IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after acquiring an additional 32 shares in the last quarter. Virtus Advisers LLC purchased a new position in IDEXX Laboratories during the 3rd quarter valued at $26,000. Finally, WealthCollab LLC bought a new position in IDEXX Laboratories in the 2nd quarter worth $30,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $556.69 on Tuesday. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98. The company has a market capitalization of $43.86 billion, a P/E ratio of 39.15, a price-to-earnings-growth ratio of 2.96 and a beta of 1.54. The firm has a 50 day moving average of $559.23 and a 200 day moving average of $572.70. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter last year, the firm posted $3.50 EPS. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IDXX. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Barclays cut their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Citigroup increased their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, UBS Group lifted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $747.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.